Pfizer · NSE: PFIZER · BSE: 500680
Q3 FY26 results · Oct–Dec 2025
Pfizer reported revenue from operations of ₹645.03 crore (up 19.9% from Q3 FY25) and net profit of ₹141.84 crore (up 11.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a standalone basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 645.03 | 537.99 | +19.9% | 642.34 | +0.4% |
| Other income | 38.21 | 42.76 | −10.6% | 41.85 | −8.7% |
| Total income | 683.24 | 580.75 | +17.6% | 684.19 | −0.1% |
| Profit before tax | 191.95 | 172.44 | +11.3% | 255.37 | −24.8% |
| Net profit for the period | 141.84 | 127.60 | +11.2% | 189.02 | −25.0% |
| EPS, basic (₹) | 31.01 | 27.89 | +11.2% | 41.32 | −25.0% |
| Net margin (%) | 22.0 | 23.7 | 29.4 |
Standalone
- Filed with BSE
- 09 Feb 2026, 19:33 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE